Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial

ConclusionThe DBPC trial showed AIT for house dust mite allergens was effective and safe in elderly patients with allergic rhinitis.Trial registrationThis randomized, double-blinded placebo-controlled (DBPC) trial was conducted at one centre (ClinicalTrials.gov no.NCT03209245)

http://link.springer.com/10.1186/s13601-017-0180-9

Source: Clinical and Translational Allergy - December 1, 2017 Category: Allergy & Immunology Source Type: research